<div id="readability-page-1"><p><span>Guardant Health (NASDAQ:GH - Get Free Report)</span>'s stock had its &#34;outperform&#34; rating reiterated by stock analysts at William Blair in a report released on Thursday,RTT News reports.</p><div><p><span></span><span>Get <strong>Guardant Health</strong> alerts:</span></p></div><ul><li>4 Healthcare Stocks With Massive Gains—and More to Come</li></ul><p>GH has been the topic of a number of other research reports. Raymond James Financial raised their price objective on Guardant Health from $59.00 to $61.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, July 31st. Scotiabank boosted their price objective on Guardant Health from $57.00 to $60.00 and gave the company a &#34;sector outperform&#34; rating in a research report on Thursday, July 31st. Mizuho lifted their price target on Guardant Health from $60.00 to $65.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, June 13th. JPMorgan Chase &amp; Co. lifted their target price on Guardant Health from $60.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday. Finally, UBS Group upped their price objective on Guardant Health from $70.00 to $80.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday. One analyst  has rated the stock with a Strong Buy rating and twenty-one have assigned  a Buy rating to the stock. Based on data from MarketBeat, Guardant Health  has a consensus rating of &#34;Buy&#34; and an average target price of $62.95.</p><p><b>Check Out Our Latest Stock Analysis on Guardant Health</b></p><h2>Guardant Health Price Performance</h2><ul><li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li></ul><p>Shares of NASDAQ:GH traded up $3.23 during mid-day trading on Thursday, reaching $60.90. 2,124,473 shares of the company traded hands, compared to its average volume of 2,396,983. The company's 50 day moving average price is $55.08 and its 200-day moving average price is $48.55. Guardant Health has a 52 week low of $20.14 and a 52 week high of $68.00. The firm has a market cap of $7.59 billion, a PE ratio of -18.14 and a beta of 1.46. </p><p>Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. During the same quarter in the prior year, the company posted ($0.84) earnings per share. The firm's revenue was up 31.0% compared to the same quarter last year.  Guardant Health has set its FY 2025 guidance at  EPS. On average, research analysts predict that  Guardant Health will post -2.9 earnings per share for the current fiscal year. </p><h2>Insider Buying and Selling</h2><ul><li>3 Fast-Growing Stocks Analysts See Doubling in Price</li></ul><p>In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the completion of the sale, the chief executive officer directly owned 1,971,830 shares of the company's stock, valued at $100,326,710.40. This trade represents a 4.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the sale, the director owned 851 shares of the company's stock, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 402,691 shares of company stock valued at $23,069,965. 6.10% of the stock is owned by corporate insiders. </p><h2>Institutional Trading of Guardant Health</h2><p>Several large investors have recently added to or reduced their stakes in GH. IFP Advisors Inc lifted its stake in  Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company's stock worth $33,000 after acquiring an additional 334 shares in the last quarter.  Signaturefd LLC boosted its stake in shares of  Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company's stock valued at $33,000 after buying an additional 213 shares in the last quarter.  Allworth Financial LP raised its holdings in  Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company's stock worth $37,000 after purchasing an additional 552 shares during the last quarter.  FNY Investment Advisers LLC acquired a new position in  Guardant Health in the second quarter valued at $62,000.  Finally, SVB Wealth LLC purchased a new stake in  Guardant Health during the first quarter valued at about $54,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Guardant Health Company Profile</h2> (Get Free Report)<p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Guardant Health</li><li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li><li>Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon</li><li>Stock Dividend Cuts Happen Are You Ready?</li><li>Why Traders Are Doubling Down on SoundHound Stock After Big Rally</li><li>Financial Services Stocks Investing</li><li>Lithium Americas Rally Lifts Other Rare Earth Stocks </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2><p>Before you consider Guardant Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p><p>While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>William Blair has reiterated an "outperform" rating for Guardant Health (NASDAQ:GH) shares. The stock has received positive ratings from several analysts, with price targets raised by Raymond James, Scotiabank, Mizuho, JPMorgan, and UBS. Guardant Health's stock traded at $60.90, with a market cap of $7.59 billion. The company reported a revenue increase of 31% year-over-year, with an EPS of ($0.44) for the last quarter. Insider trading activity included significant sales by CEO Amirali Talasaz and Director Medina Manuel Hidalgo.</p>

Guardant Health's (GH) "Outperform" Rating Reiterated at William Blair